(All fields required)
Please enter a valid email.
Please enter your name.
The Musculoskeletal Tumor Center is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.
Rajaram Nagarajan, MD, MS Associate Director, Oncology Clinical Operations 513-636-0670 email@example.com
Associate Director, Oncology Clinical Operations
Associate Professor, UC Department of Pediatrics
Bone tumors; late effects of pediatric cancer therapy
BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002.
Certifications: Pediatrics, Pediatric Hematology / Oncology.
Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011 Feb 1;117(3):625-34.
Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3.
Nagarajan R. Quality of life (QOL) in patients with osteosarcoma. Recent Results Cancer Res. 2009;179:339-44.
Nagarajan R, Mogil R, Neglia JP, Robison LL, Ness KK. Self-reported global function among adult survivors of childhood lower-extremity bone tumors: a report from the Childhood Cancer Survivor Study (CCSS). J Cancer Surviv. 2009 Mar;3(1):59-65.
Zebrack BJ, Zevon MA, Turk N, Nagarajan R, Whitton J, Robison LL, Zeltzer LK. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007 Jul;49(1):47-51.
Khan K, Schwarzenberg SJ, Sharp H, Jessurun J, Gulbahce HE, Defor T, Nagarajan R. Diagnostic endoscopy in children after hematopoietic stem cell transplantation. Gastrointest Endosc. Sep 2006;64(3):379-85.
Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clinical Obstetrics and Gynecology. Sep 2006; 49(3):464-79.
Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep. 2005 Nov;7(6):410-4.
Nagarajan R, Robison LL. Pregnancy outcomes in survivors of childhood cancer. J Natl Cancer Inst Monogr. 2005;(34):72-6.
Spector LG, Ross JA, Nagarajan R. Epidemiology of bone and soft tissue sarcomas. In Pappo A (Ed.) Pediatric Bone and Soft Tissue Tumors. 1st ed. Berlin: Springer-Verlag, 2006.
John P. Perentesis, MD, FAAP Director, Division of Oncology and Cancer Programs 513-636-8241 firstname.lastname@example.org
Director, Division of Oncology and Cancer Programs
Deb Kleisinger Endowed Chair of Novel Cancer Treatments
Executive Co-Director, Cancer and Blood Diseases Institute
Director, Leukemia / Lymphoma Program
Cincinnati Children's Principal Investigator, Children’s Oncology Group (COG)
Cincinnati Children's Principal Investigator, National Cancer Institute Pediatric Phase 1 Consortium
Professor, UC Department of Pediatrics
Acute myeloid leukemia; neuroblastoma; PNET / Ewing's sarcoma and osteosarcoma; new anticancer drug development; Phase I clinical trials
John P. Perentesis, MD, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs, and discovered genes important in the growth of normal and malignant cells. His laboratory is also developing the use of tumor and patients genetics research for personalizing therapies. In clinical research, he serves in leadership roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI Pediatric Phase I Consortium.
In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national Executive Committee for the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest, cooperative children's cancer research entity. He also is in leadership efforts in the COG for new therapies for leukemia, and adolescent and young adult cancers.
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology/Oncology, 1990.
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. . Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Jun 3.
Davies SM, Perentesis JP. Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatr Blood Cancer. 2011 Jun;56(6):895-6.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45.
Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1;14(23):7896-9.
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb;144(3):388-94.
Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.
Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May;7(5):1237-45.
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb;22(2):265-72.
Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet. 2006 Feb;165(1):75-8. Review.
Joseph G. Pressey, MD Director, Musculoskeletal Tumor Program 513-803-9083 email@example.com
Director, Musculoskeletal Tumor Program
Program Leader, Young Adult Oncology Center
Musculoskeletal tumors including rhabdomyosarcoma and other soft-tissue sarcomas; Ewing sarcoma; osteosarcoma; pediatric solid tumors; rare tumors including small cell carcinoma of the ovary.
Dr. Pressey graduated from the University of Georgia and the Medical College of Georgia before pursuing pediatrics residency training at Cincinnati Children’s Hospital Medical Center. He trained in pediatric hematology-oncology at the Children’s Hospital of Philadelphia where he developed a keen interest in pediatric sarcomas. He spent 11 years at the University of Alabama at Birmingham School of Medicine and Children’s Hospital of Alabama where he functioned as the principal investigator (PI) for the Children’s Oncology Group (COG) phase 1 and Pilot Consortium and the Sarcoma Alliance for Research through Collaboration (SARC).
Dr. Pressey joined the Cancer and Blood Diseases Institute at Cincinnati Children’s to direct the musculoskeletal tumor program. He is appointed clinical associate professor at the University of Cincinnati School of Medicine and functions as the Cincinnati Children’s Institutional PI for SARC. Dr. Pressey’s research is focused on the development of novel therapies for high-risk and recurrent/refractory solid tumors. Accordingly, he is developing a phase I trial for the COG phase I consortium and bench to bedside investigator initiated trials in collaboration with other investigators nationally.
MD: Medical College of Georgia, Augusta, GA, 1995.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1998.
Fellowship: Pediatric Hematology-Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 2001.
Certification: Pediatric Hematology-Oncology, 2002.
Kaylani SZ, Xu J, Srivastava RK, Kopelovich L, Pressey JG, Athar M. Rapamycin Targeting mTOR and Hedgehog Signaling Pathways Blocks Human Rhabdomyosarcoma Growth in Xenograft Murine Model. Biochem Biophys Res Commun. 2013 Jun 14;435(4):557-61.
Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WPD, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Bodour S, Prat J, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RBS, Cunliffe HE, Huntsman DG, Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations of SMARCA4. Nat Genetics. 2014 May;46(5):427-9.
Pressey JG, Kelly DR, Hawthorne HT. Successful treatment of preadolescents with small cell carcinoma of the ovary hypercalcemic type. J Pediatr Hematol Oncol. 2013 Oct;35(7):566-9.
Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY, Friedman GK. CD133 Marks a Myogenically Primitive Subpopulation in Rhabdomyosarcoma Cell Lines that are Relatively Chemoresistant but Sensitive to Mutant HSV. Pediatr Blood Cancer. 2013 Jan; 60(1):45-52.
Pressey JG, Anderson JR, Crossman DK, Lynch JC, Barr FG. Hedgehog Pathway Activity in Pediatric Embryonal Rhabdomyosarcoma and Undifferentiated Sarcoma: A Report from the Children’s Oncology Group. Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8.
Pressey JG, Pressey CS, Kelly DR, Robinson G, Herron R, Wilson L, Kim H. 2D-Difference Gel Electrophoretic Proteomic Analysis of a Cell Culture Model of Alveolar Rhabdomyosarcoma. J Proteome Res. 2011 Feb 4;10(2):624-36.
Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets C, Kopelovich L, Athar M. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010 Aug 15;70(16):6566-76.
Friedman GF, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies. Mol Ther. 2009 Jul;17(7):1125-35.
Siegel HJ, Pressey JG. Current Concepts in the Surgical and Medical Management of Osteosarcoma. Expert Rev Anticancer Ther. 2008 Aug;8(8):1257-69.
Womer RB, Pressey JG. Rhabdomyosarcoma and soft tissue sarcoma in childhood. Curr Opin Oncol. 2000 Jul ;12: 337-44.
Brian K. Turpin, DO 513-636-4266 firstname.lastname@example.org
Assistant Professor, UC Department of Pediatrics
Brian K. Turpin, DO, completed his undergraduate training at the University of Missouri, graduate medical training at the Kansas City University of Medicine and Biosciences, and pediatric residency and hematology / oncology fellowship at Cincinnati Children’s Hospital Medical Center where he served as co-chief fellow.
Dr. Turpin’s clinical and academic interests pertain to children and young adults with solid tumors, particularly sarcomas and neuroblastomas, with a research focus on the development of new drugs and clinical trials for patients with relapsed cancer.
DO: Kansas City University of Medicine and Biosciences.
Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center.
Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cancer and Blood Diseases Institute.
Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot Study of Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) Combined with Bevacizumab in Pediatric Patients with Recurrent Solid Tumors or Brain Tumors. Pediatr Blood Cancer. 2013 Apr 29.
Turpin BK, Morris VR, Lemen L, Weiss BD, Gelfand MJ. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy. Health Phys. 2013 Feb; 104(2 Suppl 1):S43-6.
Trehan I, Turpin BK. Neonatal respiratory distress due to bilateral dacrocystoceles. J Pediatr. 2008 Sep;153(3):438.
Turpin B, Tobias JD. Perioperative management of a child with short-chain acyl-CoA dehydrogenase deficiency. Paediatr Anaesth. 2005 Sep;15(9):771-7.
Cogar BD, Groshong TD, Turpin BK, Guajardo JR. Chylothorax in Henoch-Schonlein purpura: a case report and review of the literature. Pediatr Pulmonol. 2005 Jun;39(6):563-7.
Joel I. Sorger, MD Co-Director, Musculoskeletal Tumor Center 513-636-4787 email@example.com
Co-Director, Musculoskeletal Tumor Center
Director, Pediatric Joint Replacement Surgery
Orthopaedic oncology (sarcoma surgery) and joint replacement surgery
BS: Biology, University of Richmond, VA, August 1983-May 1987.
MD: Medical College of Virginia, Richmond, VA, August 1987-May 1991. Intern: General Surgery Intern, University of Cincinnati, Cincinnati, OH, July 1991-June 1992. Residency: General surgery resident, University of Cincinnati College of Medicine, 1992-1993; Orthopaedic surgery resident, University of Cincinnati College of Medicine, 1994-1998.
Fellowship: Orthopaedic research fellow, Noyes-Giannestras Biomechanics Lab, University of Cincinnati Department of Aerospace Engineering, 1993-1994. Bone and Soft Tissue Sarcoma Management Fellowship (Orthopaedic Oncology) , Harvard University, Massachusetts General Hospital and Boston, Children’s Hospital, August 1998-July 1999.
Certification: American Board of Orthopaedic Surgeons.
Zbojniewicz AM, Sorger JI. Posttreatment Imaging of Pediatric Musculoskeletal Tumors.
RadioGraphics. 2014 34:724-740.
Wind, M, Swank, M, Sorger J. Short-term Results of a Custom Triflange Acetabular Component for Massive Acetabular Bone Loss in revision THA.
Orthopaedics. 2013 March 36(3):e260-65.
Squires JH, Emery KH, Johnson N, Sorger J. Tibial nerve interneural ganglion cyst in a 10-year old boy.
Pediatr Radiol. Nov 8, 2012.
Mierzwa ML, McCluskey CM, Barrett WL, Lowy A, Sussman J, Sorger J. Interstitial brachytherapy for soft tissue sarcoma: A single institution experience.
Brachytherapy. 2007 Oct-Dec;6(4):298-303.
Mutema GK, Sorger J. Intraosseous Schwannoma of the Humerus. Skeletal Radiol. 2002 Jul;31(7):414-21.
Hornicek FJ, Gebhardt MC, Tomford WW, Sorger JI, Zavatta, M,Menzner Related Articles JP, Mankin HJ. Factors affecting nonunion of the allograft-host junction.
Clin Orthop Relat Res. 2001 Jan;(382):87-98.
Sorger JI, Hornicek FJ, Zavatta M, Menzner JP, Gebhardt MC, Tomford WW, Mankin HJ. Allograft Fractures Revisited.
Clin Orthop Relat Res. 2001 Jan;(382):66-74.
Hornicek FJ, Gebhardt MC, Sorger JI, Mankin HJ. Tumor Reconstruction.
Orthop Clin North Am. 1999 Oct;30(4):673-84.
Sorger, J, Kirk P, Ruhnke C, Bjornson S, Levy M, Cockrin J, Tang P. Once Daily High Dose Versus Divided, Low Dose Gentamicin for Open Fractures.
Clinical Orthopaedic and Related Research. 1999 Sep;(366):197-204.
Sorger J, Kirk P. Failure of an Implant after Total Shoulder Arthroplasty.
JBJS. 1997 79;(4):597-8.
Sorger J, Federle D, Kirk P. The Posterior Cruciate Ligament in Total Knee Arthroplasty.
J Arthroplasty. 1997;12(8).
Stella M. Davies, MBBS, PhD, MRCP Director, Bone Marrow Transplantation and Immune Deficiency 513-636-1371 firstname.lastname@example.org
Director, Bone Marrow Transplantation and Immune Deficiency
Jacob G. Schmidlapp Endowed Chair
MBBS: University of Newcastle-Upon-Tyne, England, 1981.
Clinical and Fellowship Training: The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital, 1981 to 1985.
PhD: University of Newcastle-Upon-Tyne, England, 1989.
Pediatric Fellowship: University of Minnesota, Minneapolis, MN, 1989 to 1993.
Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, Mo J, Myers K, Smolarek TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome -- acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010 Dec;203(2):180-6.
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.
Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31.Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62.
Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. Patient-derived granulocyte / macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2009 Mar;15(3):360-6.
Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009 Mar;15(3):279-92. Review.
Sonata Jodele, MD 513-636-1565 email@example.com
Bone marrow transplantation
MD: Vilnius University School of Medicine, 1988-1994.
Residency: Pediatrics, Downstate HSC at Brooklyn, Brooklyn, NY, 1998-2001.
Fellowship: Pediatric Hematology Oncology, Children's Hospital Los Angeles and Saban Research Institute, Keck School of Medicine University of Southern California, Los Angeles, CA, 2001-2004.
Certifications: Pediatrics, 2001; Pediatric Hematology / Oncology, 2004.
Licenses: California, 2001-present; Ohio, 2004-present.
Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM, Davies SM. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion. 2012 Jul 15;1537-2995.
Chima R, Rodney DC, Mi-Ok K, Li D, Wheeler DS, Davies SM, Jodele S. Improved Outcomes for Stem Cell Transplant Recipients Requiring Pediatric Intensive Care. Pediatric Critical Care Medicine. 2012.
Laskin BL, Nehus E, Goebel J, Khoury JC, Davies SM, Jodele S. Cystatin C-estimated Glomerular Filtration Rate in Pediatric Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2012 Jun 16.
Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplant associated-thrombotic microangiopathy. Blood. 2011 May 19.
Haines HL, Laskin BL, Goebel J, Davies SM, Yin HJ, Lawrence J, Mehta PA, Bleesing JJ, Filipovich AH, Marsh RA, Jodele S. Blood, and Not Urine, BK Viral Load Predicts Renal Outcome in Children with Hemorrhagic Cystitis following Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2011 Mar 6. Smith AR, Majhail NS, Macmillan ML, Defor TE, Jodele S, Lehmann LE, Krance R, Davies SM. Hematopoietic cell transplantation comorbidity index predicts transplant outcomes in pediatric patients. Blood. 2011 Jan 12.Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.
Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.
Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006 Mar;25(1):35-43.
Jodele S, Chantrain CF, Blavier L, Lutzko C, Crooks GM, Shimada H, Coussens LM, Declerck YA. The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res. 2005 Apr 15;65(8):3200-8.
Rachid Drissi, PhD 513-803-0674 firstname.lastname@example.org
Margol A, Robison N, Gnanachandran J, Hung LT, Kennedy R, Vali M, Muthugounder S, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Fouladi M, Gilles FH, Judkins AR, Sposto R, Asgharzadeh S. Tumor Associated Macrophages in SHH Subgroup of Medulloblastomas. Clin Cancer Res. 2014 Oct 24.
Dorris K, Sobo M, Onar-Thomas A, Panditharatna E, Stevenson CB, Gardner SL, DeWire MD, Pierson CR, Rempel SA, Olshefski R, Goldman S, Miles L, Fouladi M, Drissi R*. Prognostic Significance of Telomere Maintenance Mechanisms in Pediatric High-Grade Gliomas. Journal of Neuro-Oncology. 2014 Jan 30. (*senior author)
Thompson PA, Drissi R*, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Weigel BJ, Blaney SM. A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Study (ADVL1112). Clin Cancer Res. 2013 Oct 4. (*biology chair)
Sturm D, Witt H, Hovestadt V, Quang DK, Jones DTW, Konermann C, Pfaff E, Sill M, Bender S, Kool M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Rizhova M, Tönjes M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald M, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Milde T, Witt O, Lindroth A, Schwartzentruber J, Faury D, Zakrzewska M, Zakrzewski K, Liberski PP, Zapatka M, Hauser P, Garami M, Klekner A, Bognar L, van Sluis P, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of glioblastoma. Cancer Cell. 2012;22:425-437.
Drissi R*, Bockhold CA, Wu J, Dome JS*. Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells. Cancer Prev Res. 2011;4(12):1973-1981. (*joint senior author)
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Shwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambroock PJ, Andreassen PR, Wiesmüller L, Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011;39(17):7465-7476.
Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004 Sep 15;22(18):3790-7.
Drissi R*, Bakkenist CJ*, Wu J, Kastan MB, Dome JS. Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res. 2004;64:3748-3752. (*equal contribution).
Drissi R, Zindy F, Roussel MF, Cleveland JL. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem. 2001 Aug 10;276(32):29994-30001.
Stigger E, Drissi R, Lee SH. Functional analysis of human replication protein A in nucleotide excision repair. J Biol Chem. 1998 Apr 10;273(15):9337-43.
Joseph S. Palumbo, MD 513-636-4266 email@example.com
Interactions between the hemostatic system and innate immunity effecting tumor progression; Langerhans' cell histiocytosis
Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KC, Shi K, Spek CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo JS. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011 Jul 25.
Flick MJ, Chauhan AK, Frederick M, Talmage KE, Kombrinck KW, Miller W, Mullins ES, Palumbo JS, Zheng X, Esmon NL, Esmon CT, Thornton S, Becker A, Pelc LA, Di Cera E, Wagner DD, Degen JL. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood. 2011 Jun 9;117(23):6326-37.
Akunuru S, Palumbo J, Zhai QJ, Zheng Y. Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. PLoS One. 2011 Feb 9;6(2):e16951.
Palumbo JS, Degen JL. Mechanisms coupling the hemostatic system to colitis-associated cancer. Thromb Res. 2010 Apr;125 Suppl 2:S39-43. Review.
Steinbrecher KA, Horowitz NA, Blevins EA, Barney KA, Shaw MA, Harmel-Laws E, Finkelman FD, Flick MJ, Pinkerton MD, Talmage KE, Kombrinck KW, Witte DP, Palumbo JS. Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fibrinogen. Cancer Res. 2010 Apr 1;70(7):2634-43.
Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost. 2008 Mar;34(2):154-60. Review.
Palumbo JS, Barney KA, Blevins EA, Shaw MA, Mishra A, Flick MJ, Kombrinck KW, Talmage KE, Souri M, Ichinose A, Degen JL. Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function. J Thromb Haemost. 2008 May;6(5):812-9.
Palumbo JS, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 2007;120 Suppl 2:S22-8.
Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest. 2007 Nov;117(11):3224-35.
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007 Jul 1;110(1):133-41.
Dao Pan, PhD 513-636-6315 Dao.Pan@cchmc.org
Hematopoietic stem cells; mesenchymal stem/progenitor cells; gene therapy; human genetics; translational research; lysosomal storage diseases
Wang D, El-Amouri SS, Dai M, Kuan A, Hui D, Brady RO and Pan D. Engineering a lysosomal enzyme with receptor-binding domain of ApoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci USA, 110:2999-3004, 2013.
El-Amouri SS, Cao P, Miao CH and Pan D. Secreted luciferase for in vivo evaluation of systemic protein delivery in mice, Mol Biotech, 53:63-73, 2013.
Pan D*, Kalfa TA, Wang D, Risinger M, Crable S, Ottlinger A, Mount DB, Hubner CA, Franco RS, and Joiner CH*. KCl cotransporter gene expression during human and murine erythroid differentiation, J Biol Chem, 286(35): 30492-30503, 2011. co-correspondent authors.
Pan D. Cell- and Gene-Based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses. Curr Pharm Biotechnol. 2011 Jan 11.
Kalfa TA, Pushkaran S, Zhang X, Johnson JF, Pan D, Daria D, Geiger H, Cancelas JA, Williams DA, Zheng Y. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica. 2010 Jan;95(1):27-35.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Pan D. In situ (in vivo) gene transfer into murine bone marrow stem cells. Methods Mol Biol. 2009;506:159-69.
Wang D, Worsham DN, Pan D. Co-expression of MGMT(P140K) and alpha-L-iduronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction. J Gene Med. 2008 Mar;10(3):249-59.
Pan D, Sciascia A 2nd, Vorhees CV, Williams MT. Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome. Brain Res. 2008 Jan 10;1188:241-53.
Worsham DN, Schuesler T, von Kalle C, Pan D. In vivo gene transfer into adult stem cells in unconditioned mice by in situ delivery of a lentiviral vector. Mol Ther. 2006 Oct;14(4):514-24.
Nancy Ratner, PhD Beatrice C. Lampkin Chair, Cancer Biology 513-636-9469 firstname.lastname@example.org
Beatrice C. Lampkin Chair, Cancer Biology
Program Leader, Cancer and Biology and Neural Tumors Program
Preclinical testing in neurofibromatosis tumors
Nancy Ratner, PhD, is interested in understanding mechanisms of peripheral nerve tumor (neurofibroma) formation in neurofibromatosis type 1 (NF1), a common inherited disorder in which children are predisposed to cancer of the nervous system, to learning problems, bone disorders, and other cancers. She identified EGFR and MEK as potential therapeutic targets in NF1 peripheral nerve tumorigenesis, and has developed cell culture and mouse models of NF1 nerve tumorigenesis. Her laboratory has also used analysis of gene expression to identify critical genes in neurofibroma and their malignant derivatives, MPNST.
Dr. Ratner received her bachelor's from Brown University, her doctorate from Indiana University, and was a postdoctoral fellow at Washington University in St. Louis. She was a member of the faculty at the University of Cincinnati from 1987 to 2004. Dr. Ratner is currently a professor in the Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, and the program leader for Cancer Biology and Neural Tumors Program in the Cancer and Blood Diseases Institute where she holds the Beatrice C. Lampkin Endowed chair in cancer biology and serves as PI of the NINDS P50 “Cincinnati Center in NF Research.”
Dr. Ratner is an active member of the International Consortium on the Molecular Biology of NF1, NF2, and Schwannomatosis and was a member of the advisory board for the National Neurofibromatosis Foundation (now Children’s Tumor Foundation) from 1989 to 2007. She chaired the Department of Defense Neurofibromatosis Research Program Integration Panel in 2008, and currently serves as a member of the James McDonnell Brain Tumor Research Advisory Board. She received the von Recklinghausen Award from the Children’s Tumor Foundation in 2010 and the Jacob K. Javits Neuroscience Investigator Award (NIH-NINDS MERIT Award) in 2014.
PhD: Indiana University, 1982.
BA: Brown University, 1975.
Fellowship: Washington University St. Louis, 1982-1987.
Mayes DA, Rizvi TA, Titus-Mitchell HA, Oberst R, Ciraolo GM, Vorhees CV, Robinson AP, Miller SD, Stemmer-Rachamimov AO, Ratner N. Nf1 loss and Ras activation in Oligodendrocytes induce NOS-driven Defects in Myelin and Vasculature. Cell Reports. 2013 Sep 26;4(6):1197-212.
Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity B, Beckmann DA, Wolf N, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra S, Ratner N, Largaespada DA. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies novel genes and genetic pathways driving tumorigenesis. Nature Genetics. 2013;45(7):756-66.
Watson AL, Rahrmann EP, Moriarity B, Choi K, Conboy C, Greeley A, Halfond A, Anderson L, Wahl B, Keng VW, Rizzardi A, Forser C, Collins MH, Sarver A, Wallace M, Schmechel S, Ratner N, Largaespada DA. Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance. Cancer Discov. 2013 Jun;3(6):674-689.
Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, West BL, Bollag G, Ratner N. Neurofibroma associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neurpathol. 2013;125(1):159-68.
Jessen WJ, Miller SJ, Jousma E, Rizvi TA, Eaves D, Wu J, Widemann B, Kim M-O, Dombi E, Dudley AH, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N. MEK Inhibition Exhibits Efficacy in Human and Mouse Neurofibromatosis Tumors Despite Transcriptional Feedback onto ERK. J Clin. Invest. 2013 Jan 2;123(1):340-7.
Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N. Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target. Clin Canc Res. 2012 Sep 15;18(18):5020-30.
Hennigan RF, Moon CO, Parysek LM, Monk KR, Morfini G, Berth S, Brady ST, Ratner N. Merlin Modulates Microtubule-Based Vesicle Trafficking via Rac, MLK and p38SAPK. Oncogene. 2012;29(3):368-79.
Mayes DA, Rizvi TA, Cancelas JA, Kolasinski NT, Ciraolo GM, Stemmer-Rachamimov AO, Ratner N. Perinatal or Adult Nf1 Inactivation Using Tamoxifen-Inducible PlpCre Each Cause Neurofibroma Formation. Cancer Res. 2011 Jul 1;71(13):4675-85.
Hummel TR, Jessen WJ, Miller SC, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page G, Worley P, Aronow BJ, Schorry E, Ratner N. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res. 2010;16 5048-57.
Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga A, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N. Integrative genomic analyses of neurofibromatosis tumors identify SOX9 as biomarker and survival gene. EMBO Mol Medicine. 2009 1(4): 236-48.
Mitogenic Activities in Neurofibromatosis. Principle Investigator. Sept 2011-2016. NIH-R01 NS 28840-20.
Preclinical Testing: GEM-Neurofibroma. Principal Investigator. Children's Tumor Foundation. Aug 2013 - Jul 2016.
Cellular and Molecular Contributors to Neurofibroma Formation. Principal Investigator. U.S. Army NF Program. Jul 2012 - Jun 2015. DOD W81XWH-11-1-0057
Identification of Neurofibroma Growth and Drug Resistance Pathways. Principal Investigator. Neurofibromatosis Therapeutic Acceleration Program (NTAP). Apr 2014 - Mar 2016.
Ras Proteins in Nerve Tumorigenesis. Principal Investigator. Apr 2014 - Mar 2019. 1R01 NS083580-01A1.
Novel Combinatorial Therapies for Malignant Peripheral Nerve Sheath Tumors. Co-Principal Investigator. Jul 2014 - Jun 2016. 1R21NS084885-01A1.
Disordered Wnt/b-catenin signaling in MPNST Development and Maintenance. Co-Principal Investigator. Oct 2014 - Sep 2019. 1R01NS086219-01A1.
Can targeted therapy prevent neurofibroma growth in mice? Principal Investigator. Neurofibromatosis Therapeutic Acceleration Program (NTAP). Sep 2014 - Aug 2016.
Janos Sumegi, MD, PhD 513-636-5976 email@example.com
Lymphoproliferative disease; hemophagocytic lymphohistiocytosis; usher syndrome
MD: University Medical School of Debrecen, Hungary, 1968.PhD: Research Center of the Hungarian Academy of Science, Budapest, Hungary, 1974.
Docent (DMSc): Karolinska Institute Stockhom, Sweden, 1982.
Sumegi J, Barnes MG, Nestheide SV, Molleran-Lee S, Villanueva J, Zhang K, Risma KA, Grom AA, Filipovich AH. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011 Apr 14;117(15):e151-60.
Sumegi J, Nishio J, Nelson M, Frayer RW, Perry D, Bridge JA. A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor. Mod Pathol. 2011 Mar;24(3):333-42. Huang D, Sumegi J, Dal Cin P, Reith JD, Yasuda T, Nelson M, Muirhead D, Bridge JA. C11orf95-MKL2 is the resulting fusion oncogene of t(11;16)(q13;p13) in chondroid lipoma. Genes Chromosomes Cancer. 2010 Sep;49(9):810-8.Sumegi J, Streblow R, Frayer RW, Dal Cin P, Rosenberg A, Meloni-Ehrig A, Bridge JA. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2010 Mar;49(3):224-36.
Sumegi J, Johnson J, Filipovich A, Zhang K, Marsh R. Lymphoproliferative Disease, X-Linked. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993- 2004 Feb 27 [updated 2009 Jun 18]. Trizzino A, zur Stadt U, Ueda I, Risma K, Janka G, Ishii E, Beutel K, Sumegi J, Cannella S, Pende D, Mian A, Henter JI, Griffiths G, Santoro A, Filipovich A, Aricò M; Histiocyte Society HLH Study group. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J Med Genet. 2008 Jan;45(1):15-21.
Erdos M, Alapi K, Balogh I, Oroszlán G, Rákóczi E, Sümegi J, Maródi L. Severe Shwachman-Diamond syndrome phenotype caused by compound heterozygous missense mutations in the SBDS gene. Exp Hematol. 2006 Nov;34(11):1517-21. Lee SM, Sumegi J, Villanueva J, Tabata Y, Zhang K, Chakraborty R, Sheng X, Clementi R, de Saint Basile G, Filipovich AH. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50delT mutation. J Pediatr. 2006 Jul;149(1):134-7.
Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest. 2006 Jan;116(1):182-92. Tabata Y, Villanueva J, Lee SM, Zhang K, Kanegane H, Miyawaki T, Sumegi J, Filipovich AH. Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood. 2005 Apr 15;105(8):3066-71.
Gene-Expression Profiling of Peripheral Blood Mononuclear Cells in Hemophagocytic Lymphohistiocytosis. Histiocytosis Association of America. Dec 2010 - Nov 2011.
Susanne Wells, PhD Director, Epithelial Carcinogenesis and Stem Cell Program 513-636-5986 firstname.lastname@example.org
Director, Epithelial Carcinogenesis and Stem Cell Program
Director, Postdoctoral Office
Squamous cell carcinoma; mechanisms by which the HPV oncogenes subvert the host cell machinery to promote abnormal cell growth and cancer; role of specific cellular HPV targets in viral replication and cellular transformation
Visit the Wells Lab.
Susanne Wells graduated from the University of Konstanz, Germany, with a degree in Biology. She completed her PhD in Molecular Biology at the State University of Stony Brook, NY, and her Postdoctoral Fellowship at Harvard Medical School, MA. Dr. Wells moved to Cincinnati Children's Hospital Medical Center in 2002 to study human papillomavirus infection and associated carcinogenesis.
Bahassi M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ. Rixe O. A patient-derived somatic mutation in the epidural growth factor ligand-binding domain confers increased sensitivity to cetuximab in heck and neck cancer. European J Cancer. 2013 Jul:49(10):2345-55.
Privette Vinnedge LM, Ho SM. Wikenheiser-Brokamp KA, Wells SI. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. PLoS One. 2012;7(10):e46985.
Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Butsch Kovacic M, Wikenheiser-Brokamp KA, Wells SI. The Fanconi anemia pathway limits human papillomavirus replication. J Virol. 2012 Aug;86(15);8131-8.
Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, Wells SI, Future directions and treatment strategies for head and neck squamous cell carcinomas. Transl Res. 2012 Sep;160(3):167-77.
Morrison MA, Morreale RJ, Akunuru S, Kofron M, Zheng Y, Wells SI. Targeting the human papillomavirus E6 and E7 oncogenes through expression of the BPV1 E2 protein stimulates cellular motility. J Virol. 2011 Oct;85(20):10487-98.
Myers KC, Bleesing JJ, Davies SM, Zhang X, Martin LJ, Mueller R, Harris RE, Filipovich AH, Kovacic MB, Wells SI, Mehta PA. Impaired immune function in children with Fanconi anaemia. Br J Haematol. 2011 Jul;154(2):234-40.
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmuller L, Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucl Acids Res. 2011 Sep 1;39(17):7465-76.
Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 2011 Jun 16;30:2741-52.
Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Toile K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011 Feb 3;470(733):105-9.
Meyer SE, Peace BE, Bahassi el M, Kavanaugh GM, Wagh PK, Robbins SB, Yin M,Wells SI, Zinser GM, Stambrook PJ, Waltz SE. Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice. Cancer Lett. 2010 Oct 28;296(2):186-93.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center